Mr. Speaker, for now, the minister plans on reading and analyzing what is happening in the Standing Committee on Industry, Science and Technology, which is hearing from representatives of the generic and patent drug industries and from Health Canada and Industry Canada officials.
Following these hearings, we will see if the committee makes any recommendations and at that time, we will consider the report.